| ORUKA THERAPEUTICS INC. |
| USA |
| Gesundheit |
| US6876041087 / A3DPH3 |
| HQ1 (Frankfurt) / ORKA (NASDAQ) |
| FRA:HQ1, ETR:HQ1, HQ1:GR, NASDAQ:ORKA |
| - |
| https://orukatx.com/ |
|
Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing monoclonal antibody therapies for psoriasis and other inflammatory and immunology-related conditions. Its current pipeline centers on treatments designed to ..
>Volltext.. |
| 5404.12 Mio. EUR |
| 4642.33 Mio. EUR |
| - |
| -135.43 Mio. EUR |
| -116.15 Mio. EUR |
| -2.15 EUR |
| 2.23 Mio. EUR |
| 234.66 Mio. EUR |
| -88.21 Mio. EUR |
| 38.03 |
| - |
| -37.1% |
| - |
| - |
| - |
| 5 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 9.110.619 Euro. |
| ORUKA |
| 23.09.26 |